CORRELATION BETWEEN ENVIRONMENTAL TOBACCO SMOKE (ETS) EXPOSURE AND ANAPLASTIC LYMPHOMA KINASE (ALK) RE-ARRANGEMENT POSITIVE NSCLC PATIENTS WHO ARE NEVER-SMOKERS

被引：0
|
作者：
Ou, Sai-Hong I. [1 ]
Siwak-Tapp, Christina [2 ]
Kawaguchi, Tomoya [3 ]
机构：
[1] Ctr Comprehens Canc, Dept Internal Med, Las Vegas, NV USA
[2] Chao Family Comprehens Canc Ctr, Irvine, CA USA
[3] Natl Hosp Org Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
environmental tobacco exposure; ALK re-arranged NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1501 / S1502
页数：2
相关论文
共 7 条
  • [1] Environmental Tobacco Smoke Exposure and EGFR Mutations/ALK Translocation in Never Smokers. A Multicenter Study in Spanish Never-Smokers
    Perez-Rios, Monica
    Ruano-Ravina, Alberto
    Zapata, Maruxa
    Torres-Duran, Maria
    Leiro-Fernandez, Virginia
    Parente-Lamelas, Isaura
    Vidal-Garcia, Iria
    Castro-Anon, Olalla
    Amenedo, Margarita
    Provencio-Pulla, Mariano
    Golpe Gomez, Antonio
    Guzman-Taveras, Rosirys
    Jose Mejuto-Marti, Maria
    Rodriguez, Angeles
    Barros-Dios, Juan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S448 - S449
  • [2] Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With NoneSmall-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry
    Soo, Ross A.
    Kubo, Akihito
    Ando, Masahiko
    Kawaguchi, Tomoya
    Ahn, Myung-Ju
    Ou, Sai-Hong Ignatius
    CLINICAL LUNG CANCER, 2017, 18 (05) : 535 - 542
  • [3] Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors
    Kim, D.
    Lee, J. K.
    Park, H. S.
    Kulig, K.
    Kim, T. M.
    Lee, S.
    Jeon, Y.
    Chung, D. H.
    Heo, D. S.
    Kim, W. H.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] EXPOSURE-RESPONSE (ER) RELATIONSHIP BETWEEN LORLATINIB (LOR) PLASMA EXPOSURE AND INCREASE IN BLOOD PRESSURE (BP) IN PATIENTS WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).
    Darragjati, M.
    Li, J.
    Pithavala, Y.
    Chen, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S17 - S17
  • [5] A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England
    Yip, K.
    Conibear, J.
    Woolf, D.
    Tarver, K.
    Willis, B.
    Hall, S.
    Sun, F.
    Kuhan, H.
    Lambourne, B.
    Piskilidis, P.
    Kussaibati, R.
    Martin, L.
    Satar, N. Abdul
    Gray, C. M. N.
    Khan, A.
    Doherty, G.
    Prewett, S.
    Smith, M.
    Dancey, G.
    Patterson, D. M.
    Rimmer, Y.
    Hollingdale, A.
    Ingle, C.
    Tasigiannopoulos, Z.
    Aslam, S.
    Waite, K.
    Polychronis, A.
    Ghafoor, Q.
    Baijal, S.
    Newsom-Davis, T.
    Shah, R.
    Forster, M.
    Mulatero, C.
    Greystoke, A.
    Postmus, P. E.
    Blackhall, F.
    Gilligan, D.
    LUNG CANCER, 2017, 103 : S28 - S29
  • [6] Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
    Hao, X.
    Zhang, S.
    Hu, Y.
    Zhuang, W.
    Fang, J.
    Liu, Y.
    Wang, M.
    Si, M.
    Sang, Y.
    Kang, X.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1686 - S1687
  • [7] Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028)
    Ou, S.
    Gadgeel, S.
    Chiappori, A.
    Riely, G.
    Lee, R.
    Garcia, L.
    Tatsuno, M.
    Tanaka, T.
    Gandhi, L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S19 - S19
1